{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:53:13Z","timestamp":1791337993295,"version":"4.3.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:00:00Z","timestamp":1740873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","valueinhealthjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jval.2025.02.004","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:25:27Z","timestamp":1741134327000},"page":"720-729","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Early Cost-Effectiveness Analysis of Using Whole-Genome Sequencing for Patients With Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"28","author":[{"given":"Jinjing","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Franzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Aas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Koen van der Mijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim J.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valesca P.","family":"Retel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jval.2025.02.004_bib1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"issue":"11","key":"10.1016\/j.jval.2025.02.004_bib2","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"issue":"4","key":"10.1016\/j.jval.2025.02.004_bib3","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.euf.2020.03.009","article-title":"Third-line life-prolonging drug treatment in a real-world metastatic castration-resistant prostate cancer population: results from the Dutch castration-resistant prostate cancer registry","volume":"7","author":"Notohardjo","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"suppl 1","key":"10.1016\/j.jval.2025.02.004_bib4","first-page":"S86","article-title":"Future directions for precision oncology in prostate cancer","volume":"82","author":"Mizuno","year":"2022","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.jval.2025.02.004_bib5","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1038\/s41467-019-13084-7","article-title":"The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact","volume":"10","author":"Van Dessel","year":"2019","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.jval.2025.02.004_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.jval.2025.02.004_bib7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.jval.2025.02.004_bib9","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41416-021-01663-9","article-title":"Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer","volume":"126","author":"Slootbeek","year":"2022","journal-title":"Br J Cancer"},{"issue":"16","key":"10.1016\/j.jval.2025.02.004_bib10","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.18632\/oncotarget.28015","article-title":"Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions","volume":"12","author":"Scott","year":"2021","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.jval.2025.02.004_bib11","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.3390\/ijms21124507","article-title":"The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling","volume":"21","author":"Shorning","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.jval.2025.02.004_bib12","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2012.08.053","article-title":"Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity","volume":"63","author":"Beltran","year":"2013","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.jval.2025.02.004_bib13","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.jval.2025.02.004_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/14737167.2021.1917385","article-title":"Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing","volume":"21","author":"Pasmans","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"10.1016\/j.jval.2025.02.004_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/path.5988","article-title":"Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practice","volume":"258","author":"Samsom","year":"2022","journal-title":"J\u00a0Pathol"},{"issue":"11","key":"10.1016\/j.jval.2025.02.004_bib16","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jval.2025.02.004_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12920-024-01795-w","article-title":"Whole genome sequencing in clinical practice","volume":"17","author":"Bagger","year":"2024","journal-title":"BMC Med Genomics"},{"issue":"10","key":"10.1016\/j.jval.2025.02.004_bib18","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/gim.2017.247","article-title":"Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature","volume":"20","author":"Schwarze","year":"2018","journal-title":"Genet Med"},{"issue":"12","key":"10.1016\/j.jval.2025.02.004_bib19","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s40273-021-01073-y","article-title":"Early cost effectiveness of whole-genome sequencing as a clinical diagnostic test for patients with inoperable stage IIIB,C\/IV non-squamous non-small-cell lung cancer","volume":"39","author":"Simons","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jval.2025.02.004_bib20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/14737167.2021.1917386","article-title":"Early technology assessment of using whole genome sequencing in personalized oncology","volume":"21","author":"Simons","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"5","key":"10.1016\/j.jval.2025.02.004_bib21","first-page":"215","article-title":"How useful are early economic models? Comment on \u201cproblems and promises of health technologies: the role of early health economic modelling\u201d","volume":"9","author":"Love-Koh","year":"2020","journal-title":"Int J Health Policy Manag"},{"issue":"2","key":"10.1016\/j.jval.2025.02.004_bib22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/15384047.2018.1523849","article-title":"Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing","volume":"20","author":"Ikeda","year":"2019","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"10.1016\/j.jval.2025.02.004_bib23","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41585-019-0237-8","article-title":"Towards precision oncology in advanced prostate cancer","volume":"16","author":"Ku","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.jval.2025.02.004_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/PO.17.00084","article-title":"Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data","author":"Middha","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"26","key":"10.1016\/j.jval.2025.02.004_bib28","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or Enzalutamide in Metastatic Prostate Cancer","volume":"381","author":"De Wit","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.jval.2025.02.004_bib29","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jval.2025.02.004_bib31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.euo.2022.04.004","article-title":"Immune biomarkers in metastatic castration-resistant prostate cancer","volume":"5","author":"Fenor de la Maza","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"7","key":"10.1016\/j.jval.2025.02.004_bib32","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jmoldx.2021.04.011","article-title":"Clinical validation of whole genome sequencing for cancer diagnostics","volume":"23","author":"Roepman","year":"2021","journal-title":"J\u00a0Mol Diagn"},{"issue":"2","key":"10.1016\/j.jval.2025.02.004_bib34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s41669-020-00219-6","article-title":"Treatment-related healthcare costs of metastatic castration-resistant prostate cancer in Germany: a claims data study","volume":"5","author":"Kreis","year":"2021","journal-title":"Pharmacoecon Open"},{"issue":"8","key":"10.1016\/j.jval.2025.02.004_bib36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/CAD.0000000000000648","article-title":"Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands","volume":"29","author":"Franken","year":"2018","journal-title":"Anti Cancer Drugs"},{"issue":"1","key":"10.1016\/j.jval.2025.02.004_bib37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40258-017-0350-x","article-title":"Dutch economic value of radium-223 in metastatic castration-resistant prostate cancer","volume":"16","author":"Peters","year":"2018","journal-title":"Appl Health Econ Health Policy"},{"issue":"11","key":"10.1016\/j.jval.2025.02.004_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187477","article-title":"Update of the Dutch manual for costing studies in health care","volume":"12","author":"Kanters","year":"2017","journal-title":"PLOS One"},{"issue":"3","key":"10.1016\/j.jval.2025.02.004_bib40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2165\/11586130-000000000-00000","article-title":"Standardizing the inclusion of indirect medical costs in economic evaluations","volume":"29","author":"van Baal","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.jval.2025.02.004_bib42","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3109\/0284186X.2012.760848","article-title":"Health-related quality of life in prostate cancer","volume":"52","author":"Torvinen","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jval.2025.02.004_bib43","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2147\/PPA.S44947","article-title":"Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases","volume":"7","author":"Matza","year":"2013","journal-title":"Patient Prefer Adherence"},{"issue":"24","key":"10.1016\/j.jval.2025.02.004_bib44","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jval.2025.02.004_bib45","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.jval.2025.02.004_bib46","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jval.2025.02.004_bib47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40258-017-0364-4","article-title":"Correction to: Dutch economic value of radium-223 in metastatic castration-resistant prostate cancer","volume":"16","author":"Peters","year":"2018","journal-title":"Appl Health Econ Health Policy"},{"issue":"31","key":"10.1016\/j.jval.2025.02.004_bib48","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011736","article-title":"Direct costs associated with adverse events of systemic therapies for advanced melanoma: systematic literature review","volume":"97","author":"Copley-Merriman","year":"2018","journal-title":"Med (Baltim)"},{"issue":"4","key":"10.1016\/j.jval.2025.02.004_bib49","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.eururo.2021.06.021","article-title":"Efficacy and safety of cabazitaxel versus abiraterone or enzalutamide in older patients with metastatic castration-resistant prostate cancer in the CARD study","volume":"80","author":"Sternberg","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.jval.2025.02.004_bib51","first-page":"675","article-title":"Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer","volume":"24","author":"Thurgar","year":"2021","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.jval.2025.02.004_bib53","series-title":"Dutch Population (Male) Probability of Dying Next Year in 2023","author":"Data","year":"2012"},{"issue":"9","key":"10.1016\/j.jval.2025.02.004_bib54","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12032-017-1014-2","article-title":"Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting","volume":"34","author":"Oh","year":"2017","journal-title":"Med Oncol"},{"issue":"8","key":"10.1016\/j.jval.2025.02.004_bib55","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors","volume":"38","author":"Shore","year":"2021","journal-title":"Adv Ther"},{"issue":"9747","key":"10.1016\/j.jval.2025.02.004_bib56","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jval.2025.02.004_bib57","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","article-title":"AdViSHE: A validation-assessment tool of health-economic models for decision makers and model users","volume":"34","author":"Vemer","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.jval.2025.02.004_bib58","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10198-015-0683-z","article-title":"When do performance-based risk-sharing arrangements make sense?","volume":"16","author":"Drummond","year":"2015","journal-title":"Eur J Health Econ"},{"issue":"5","key":"10.1016\/j.jval.2025.02.004_bib59","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jval.2013.04.011","article-title":"Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force","volume":"16","author":"Garrison","year":"2013","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2025.02.004_bib60","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3390\/cancers14051245","article-title":"Immune checkpoint inhibitors in advanced prostate cancer: current data and future perspectives","volume":"14","author":"Rebuzzi","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.jval.2025.02.004_bib61","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40273-021-01010-z","article-title":"Guidance for the harmonisation and improvement of economic evaluations of personalised medicine","volume":"39","author":"Vellekoop","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jval.2025.02.004_bib62","article-title":"Current status of monoclonal antibodies-based therapies in castration-resistant prostate cancer: a systematic review and meta-analysis of clinical trials","volume":"14","author":"Tarrar","year":"2022","journal-title":"Cureus"},{"issue":"10398","key":"10.1016\/j.jval.2025.02.004_bib63","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(23)01123-6","article-title":"Combining next-generation hormonal therapy with PARP inhibition in metastatic castration-resistant prostate cancer","volume":"402","author":"Abida","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jval.2025.02.004_bib64","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbae390","article-title":"Performance assessment of computational tools to detect microsatellite instability","volume":"25","author":"Anthony","year":"2024","journal-title":"Brief Bioinform"},{"issue":"3","key":"10.1016\/j.jval.2025.02.004_bib65","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s41669-018-0109-9","article-title":"Use of decision modelling in economic evaluations of diagnostic tests: an appraisal and review of health technology assessments in the UK","volume":"3","author":"Yang","year":"2019","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"10.1016\/j.jval.2025.02.004_bib66","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12863-017-0479-5","article-title":"Opportunities and challenges of whole-genome and -exome sequencing","volume":"18","author":"Petersen","year":"2017","journal-title":"BMC Genet"},{"key":"10.1016\/j.jval.2025.02.004_bib67","article-title":"Metastatic hormone-sensitive prostate cancer: toward an era of adaptive and personalized treatment","volume":"43","author":"Hamid","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525000828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525000828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T22:46:49Z","timestamp":1747349209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301525000828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1098301525000828"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2025.02.004","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Cost-Effectiveness Analysis of Using Whole-Genome Sequencing for Patients With Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2025.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}